Excited to share our paper out today in @eBioMedicine showing a single dose ChAdOx2 vaccine against Crimean-Congo Haemorrhagic Fever protected mice from lethal disease. A big team effort from all the authors, including @jenneratingVacc@CiaranGilbride
https://t.co/2hQCRQEAXe
@jacobridley78@engfac@ahrcpress Congratulations Jacob, or should I say Dr Ridley! Very excited to read this new work about the Everyman morality plays (about time) and hear about what you’ve got planned for him next 🔥
His Royal Highness The Duke of Gloucester visited Oxford University on Thursday, touring two of its leading medical research centres: the Clinical BioManufacturing Facility and the laboratories of @OxfordVacGroup and @psioxford.
More info ⬇️ @DHSCgovuk
Join our study to develop a vaccine for Crimean-Congo haemorrhagic fever (CCHF).
ℹ️2 vaccine doses given at the Oxford Vaccine Group 🏥Most participants will have a total of 11 visits
🗓️Total study duration = 12 months
Reimbursement from £1110 to £1470
https://t.co/dWsjQdqnTH
👏An Oxford Vaccine Group study has administered a new vaccine against the tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time.👏
Read more: https://t.co/bnL8xuZGhx
Congrats to the PRRS team on publishing the results from this challenge study! Loved my time with the group during my PhD placement last summer (even the 15 hour flow days with @KerryHoltham and Rory) and pleased to have been able to contribute to this work. Check it out now ⬇️⬇️
Check out the new publication from our group @PRRS_Immunol@Pirbright_Inst. The work describes the evaluation of an attenuated herpesvirus vectored vaccine candidate against PRRSV https://t.co/wugiCZO5S8